Celiac Disease Market Size, Share, Growth, and Industry Analysis, By Type (First Line of Treatment, Second Line of Treatment), By Application (Hospital, Clinic), Regional Insights and Forecast From 2026 To 2035

Celiac Disease Market Overview

The global celiac disease market is projected to reach USD 690.9 million in 2026 and expand significantly to USD 1,647.93 million by 2035. During the forecast period from 2026 to 2035, the market is expected to register a robust compound annual growth rate (CAGR) of 10.14%. This growth is anticipated to be supported by increasing disease awareness, improved diagnostic rates, and rising demand for effective celiac disease management and treatment solutions worldwide.

The USA represents a major celiac disease market because of its diagnosed population, established gastroenterology infrastructure, clinical trial activity, and standardized gluten free labeling. Approximately 2 million Americans are estimated to have celiac disease, while other epidemiological estimates place the affected population near 3 million depending on methodology. Around 1 in 100 people is affected. Foods carrying regulated gluten free claims must contain less than 20 ppm gluten, creating an established dietary management framework. Clinical development is increasingly focused on patients experiencing symptoms or intestinal injury despite maintaining gluten avoidance, supporting demand for adjunctive pharmaceutical treatments and specialized diagnostic monitoring.

Key Findings

• Market Size and Forecast: The celiac disease treatment market stands at USD 690.9 million in 2026, reaching USD 1,647.93 million by 2030 at 10.14% CAGR.
• Type Leadership: First line treatment holds an estimated 72.4% share, supported by gluten avoidance, nutritional supplementation, physician guidance, and established clinical adoption.
• Application Leadership: Hospitals account for an estimated 61.3% share, reflecting specialist gastroenterology access, biopsy procedures, serological testing, nutritional management, and clinical monitoring.
• Key Company Landscape: Takeda and Teva strengthen celiac disease therapeutics through enzyme, immune tolerance, TG2 inhibition, and IL-15 targeted clinical development programs.
• Fastest Growing Region: North America leads with 38.2% share, while Asia Pacific gains momentum through improved diagnosis, screening availability, awareness, and specialist access.
• Key Trends: Global seroprevalence is approximately 1.5%, while 0.8% biopsy confirmed prevalence supports development of enzyme therapies, immunotherapies, and mucosal protection approaches.

Latest Trends

The celiac disease market is shifting from diet centered management toward pharmaceutical approaches designed to reduce the consequences of accidental gluten exposure and modify immune responses. Global seroprevalence is approximately 1.5%, demonstrating a substantial addressable patient population for diagnosis, monitoring, nutritional support, and investigational therapies. Drug developers are evaluating gluten degrading enzymes, TG2 inhibitors, monoclonal antibodies, antigen specific immunotherapies, and immune tolerance platforms. These approaches seek to protect intestinal tissue, reduce gluten driven inflammation, improve symptoms, or restore tolerance. Digital symptom tracking and improved serological testing are also supporting patient identification and clinical trial recruitment.

Another important celiac disease market trend is greater emphasis on patients who remain symptomatic despite gluten avoidance. Biopsy confirmed prevalence is approximately 0.8% globally, supporting continued investment in therapeutic research. Clinical programs increasingly incorporate gluten challenge models, villous height measurements, intraepithelial lymphocyte assessment, patient reported symptoms, and mucosal healing endpoints. Pharmaceutical developers are additionally investigating IL-15, CD122, TG2, and gluten specific immune pathways. These mechanisms could create differentiated second line treatment options alongside dietary management rather than replacing gluten avoidance immediately.

Market Dynamics

DRIVER

"Increasing diagnosis and recognition of celiac disease."

Improved recognition of celiac disease is expanding the diagnosed population requiring dietary management, nutritional monitoring, gastroenterology services, and potential pharmaceutical treatment. Global seroprevalence is approximately 1.5%, while biopsy confirmed prevalence is approximately 0.8%. Greater physician awareness is increasing the use of tissue transglutaminase antibody testing, endomysial antibody testing, genetic assessment, and intestinal biopsy. The celiac disease market also benefits from greater understanding that the disorder can present through gastrointestinal and non gastrointestinal symptoms. Patients experiencing anemia, nutritional deficiencies, fatigue, bone complications, diarrhea, abdominal discomfort, or persistent unexplained symptoms are increasingly evaluated for celiac disease, expanding treatment demand.

Driver Impact Analysis

RESTRAINT

"Dependence on strict gluten avoidance as established disease management."

The established effectiveness of a strict gluten free diet creates a significant commercial barrier for pharmaceutical developers. Many diagnosed patients can achieve symptom improvement and intestinal recovery through dietary modification, reducing immediate demand for medication. Products marketed as gluten free in the USA must remain below 20 ppm gluten, supporting a regulated ecosystem that facilitates dietary management. Pharmaceutical candidates therefore need to demonstrate meaningful additional benefits involving symptoms, intestinal histology, accidental exposure protection, or immune modification. Clinical development is further complicated because dietary adherence varies substantially between patients, making it difficult to distinguish therapeutic effects from changes in gluten exposure and lifestyle behavior.

Restraints Impact Analysis

OPPORTUNITY

"Development of non dietary and disease modifying celiac therapies."

The absence of broadly established pharmaceutical treatment capable of replacing dietary management creates a major celiac disease market opportunity. Approximately 30% of people possess HLA DQ2 or HLA DQ8 variants associated with susceptibility, providing a large genetically relevant population for research and screening strategies. Developers are exploring gluten degrading enzymes that act before gluten reaches the small intestine, TG2 inhibitors intended to reduce immune triggering, IL-15 pathway therapies designed to control intestinal inflammation, and antigen specific platforms intended to establish immune tolerance. Successful candidates could address accidental exposure, persistent symptoms, mucosal injury, and difficult dietary adherence while complementing existing nutritional management.

CHALLENGE

"Demonstrating consistent clinical benefit across heterogeneous patient populations."

Celiac disease clinical trials face challenges involving dietary adherence, variable gluten exposure, symptom diversity, histological assessment, and differences between serological and biopsy findings. Approximately 41.4% of biopsy confirmed patients can be asymptomatic according to recent pooled evidence, illustrating the disconnect between symptoms and intestinal injury. This complicates patient selection and endpoint development. Trials must often combine patient reported outcomes with biopsy measurements, immune biomarkers, serological markers, and controlled gluten challenges. Developers also need favorable long term safety because celiac disease requires lifelong management. These requirements increase development complexity for immune modifying products intended for otherwise stable patients following gluten avoidance.

Celiac Disease Market Segmentation

The celiac disease market can be segmented by treatment line and clinical application. First line treatment accounts for an estimated 72.4% share because gluten avoidance, nutritional correction, physician monitoring, and management of deficiencies remain fundamental. Second line treatment represents 27.6%, reflecting patients requiring additional symptom management or investigational pharmaceutical approaches. By application, hospitals account for an estimated 61.3% share because they support gastroenterology consultation, endoscopy, biopsy, laboratory testing, and complicated case management. Clinics represent 38.7%, supported by routine follow up, serological monitoring, dietary counseling, nutritional assessment, and management of stable diagnosed patients requiring continuing celiac disease care.

By Type

Based on Type the global market can be categorized in to First Line of Treatment and Second Line of Treatment.

• First Line Of Treatment: First line treatment represents an estimated 72.4% of the celiac disease market under the requested treatment line segmentation. The segment primarily covers strict gluten avoidance, nutritional assessment, correction of deficiencies, patient education, and continuing clinical monitoring. Foods carrying gluten free claims in the USA must contain less than 20 ppm gluten, giving patients a standardized threshold for packaged food selection. First line treatment remains dominant because eliminating dietary gluten can permit intestinal healing and improve symptoms in many patients.

• Second Line Of Treatment: Second line treatment represents an estimated 27.6% of the celiac disease market under the requested segmentation. This category includes management strategies for persistent symptoms, nutritional complications, difficult dietary response, and emerging pharmaceutical approaches intended to supplement gluten avoidance. The development pipeline increasingly includes gluten degrading enzymes, TG2 inhibitors, immune tolerance therapies, and monoclonal antibodies targeting inflammatory pathways.

By Application

Based on Application the global market can be categorized in to Hospital and Clinic.

• Hospital: Hospitals represent an estimated 61.3% of the celiac disease market by application. Their leading position reflects access to gastroenterologists, endoscopy units, pathology services, serological testing, nutritional specialists, and multidisciplinary management for complicated disease. Diagnosis frequently involves tissue transglutaminase antibody testing followed by specialist evaluation and, when clinically appropriate, intestinal biopsy. Biopsy confirmed global prevalence is approximately 0.8%, emphasizing the importance of specialist diagnostic infrastructure.

• Clinic: Clinics account for an estimated 38.7% of the celiac disease market by application. Clinics support initial assessment, follow up testing, nutritional monitoring, symptom evaluation, dietitian referrals, and continuing management after diagnosis. Approximately 1.5% global seroprevalence indicates a substantial screening population that can enter the healthcare pathway through outpatient services. Clinics are particularly important for monitoring adherence to gluten avoidance, correcting iron or vitamin deficiencies, reviewing persistent gastrointestinal symptoms, and determining when specialist referral is required.

Celiac Disease Market Regional Outlook

• North America

North America accounts for an estimated 38.2% of the celiac disease market, making it the largest regional segment under this report framework. The region benefits from established gastroenterology networks, advanced serological testing, intestinal biopsy capacity, clinical research centers, and strong awareness of gluten related disorders. Approximately 1 in 100 people in the USA is affected by celiac disease according to commonly cited public health estimates. The USA patient population is estimated at approximately 2 million using conservative epidemiological assessment.

Foods carrying regulated gluten free claims must remain below 20 ppm gluten. These factors support demand for diagnostic services, dietary counseling, nutritional products, monitoring, and investigational pharmaceutical therapies. North America is also an important location for trials examining IL-15 inhibition, CD122 targeting, immune tolerance, and protection against gluten induced intestinal injury. Increasing identification of previously undiagnosed patients provides additional celiac disease market potential.

• Europe

Europe holds an estimated 28.5% share of the celiac disease market. The region has substantial clinical familiarity with celiac disease, established gastroenterology services, structured diagnostic pathways, and widespread recognition of gluten related dietary requirements. Biopsy confirmed prevalence has been estimated at approximately 0.8% in pooled European epidemiological analysis. Europe also contains active pharmaceutical research networks evaluating immune modulation, TG2 inhibition, mucosal protection, and approaches addressing continuing symptoms despite dietary adherence.

Strong availability of serological testing and specialist services facilitates diagnosis and long term follow up. The celiac disease market additionally benefits from high patient awareness and broad availability of gluten free food categories. European research institutions remain important participants in multinational clinical trials. Demand is increasingly shifting beyond nutritional management toward therapies designed to reduce intestinal injury caused by accidental gluten exposure and provide additional protection for patients who remain symptomatic.

• Asia Pacific

Asia Pacific accounts for an estimated 24.8% of the celiac disease market and represents a significant development opportunity. Historical underdiagnosis has increasingly given way to greater recognition, particularly across India, Australia, and specialist healthcare systems elsewhere in the region. Asian biopsy confirmed prevalence has been estimated at approximately 0.6%, while broader regional analyses demonstrate meaningful serological disease burden. India has reported approximately 0.6% pooled prevalence in epidemiological analysis, establishing celiac disease as a relevant gastrointestinal and autoimmune condition rather than a disorder confined to Western populations.

Expanding diagnostic infrastructure, greater gastroenterologist availability, increased awareness of autoimmune disease, and access to serological testing support market development. Pharmaceutical trials involving celiac disease treatments have also included Asia Pacific sites. The regional market offers opportunities in screening, nutritional monitoring, gluten free management, specialty pharmaceuticals, diagnostic technologies, and investigational therapies addressing immune responses to gluten.

• Middle East & Africa

Middle East & Africa represents an estimated 4.5% of the celiac disease market. Disease recognition varies substantially across healthcare systems, but epidemiological evidence confirms that celiac disease is clinically relevant throughout the region. Biopsy confirmed prevalence in the Middle East has been estimated at approximately 0.6%, while serological prevalence has been reported at approximately 1.6% in pooled geographic analysis. These findings support greater screening among symptomatic and genetically susceptible populations.

Market development is influenced by expanding specialist care, increasing availability of antibody testing, physician education, and growing awareness that celiac disease can produce gastrointestinal and systemic manifestations. Major urban healthcare centers provide opportunities for diagnostic laboratories, gastroenterology services, nutritional counseling, and specialist therapeutics. Limited awareness and uneven diagnostic access remain barriers, particularly where endoscopy and specialized pathology services are concentrated in major hospitals rather than broadly distributed healthcare facilities.

• Rest of the World

Rest of the World accounts for an estimated 4.0% of the celiac disease market. This segment includes markets across South America, Oceania, and other territories not separately represented within the regional framework. Epidemiological research has estimated biopsy confirmed prevalence at approximately 0.4% in South America and approximately 0.8% in Oceania. Australia and neighboring developed healthcare markets demonstrate strong awareness, diagnostic capabilities, dietary management infrastructure, and participation in celiac disease clinical research.

South American markets offer expansion potential as physician awareness, antibody testing, endoscopic diagnosis, and gluten free product availability improve. Growth opportunities are concentrated in specialist diagnostics, dietary counseling, nutritional supplementation, and pharmaceutical pipeline participation. Increasing recognition that celiac disease occurs across diverse ethnic and geographic populations supports broader screening and reduces the historical perception that the condition is predominantly associated with European ancestry.

Key Industry Players

Competition in the celiac disease market is increasingly driven by clinical differentiation rather than established prescription product dominance. Major pharmaceutical and biotechnology participants are developing gluten degrading enzymes, TG2 inhibitors, monoclonal antibodies, CD122 antagonists, IL-15 inhibitors, and antigen specific immune tolerance technologies.

Takeda has maintained a broad investigational presence through multiple celiac disease mechanisms, while Teva is advancing immune targeted development. Emerging biotechnology companies including Forte Biosciences, Barinthus Biotherapeutics, First Tracks Biotherapeutics, and Anokion have expanded clinical activity. GSK maintains extensive immunology development capabilities, although publicly disclosed celiac specific commercial positioning remains more limited than several dedicated clinical pipeline participants.

List of Top Celiac Disease Companies

• GSK

Market Leadership Matrix

List of Top 2 Companies Market Share

• GSK: GSK is a key company in the celiac disease market, supported by its established pharmaceutical research capabilities, immunology expertise, global clinical development infrastructure, and focus on innovative therapies addressing immune mediated diseases.

Investment Analysis and Opportunities

Investment activity in the celiac disease market increasingly targets therapies that could supplement strict dietary management rather than competing solely within nutritional products. Global seroprevalence of approximately 1.5% provides a sizeable potential patient base spanning diagnosed, undiagnosed, symptomatic, and asymptomatic populations.

Investment opportunities include gluten degrading enzymes, antigen specific tolerance platforms, monoclonal antibodies, TG2 inhibitors, biomarker technologies, digital symptom tracking, and diagnostic systems. Companies able to demonstrate protection against accidental gluten exposure could address a practical problem faced by patients despite careful dietary compliance. Clinical programs combining symptom outcomes with histological evidence may establish stronger differentiation.

New Product Development

New product development in the celiac disease market focuses on mechanisms capable of protecting intestinal tissue or altering the immune response to gluten. Approximately 1.5% global seroprevalence supports development across broad patient populations, while 0.8% biopsy confirmed prevalence identifies a substantial clinically confirmed group.

Investigational technologies include engineered glutenases that degrade gluten before intestinal exposure, selective TG2 inhibitors designed to interrupt disease triggering processes, IL-15 pathway antibodies targeting intestinal inflammation, CD122 antagonists affecting pathogenic immune signaling, and antigen specific platforms intended to create immune tolerance. Developers are also improving trial designs through controlled gluten challenges, histological endpoints, biomarkers, and digital symptom monitoring.

Recent Developments (2025–2026)

• January 2025: Anokion reported positive symptom findings for KAN-101, advancing an antigen specific immune tolerance approach designed to reduce gluten driven immune responses in celiac disease patients.
• May 2025: Teva received Fast Track designation for TEV-53408, an anti-IL-15 antibody designed to suppress IL-15 driven intestinal inflammation and accelerate development for celiac disease patients.
• August 2025 : Takeda posted results from its TAK-062 study, evaluating an engineered glutenase intended to degrade ingested gluten and reduce symptoms and intestinal damage following exposure.
• August 2026: Barinthus completed enrollment of 42 planned subjects in the AVALON study, advancing VTP-1000 antigen specific immunotherapy designed to promote durable immune tolerance to gluten.
• August 2026: First Tracks completed gluten challenge cohort enrollment for ANB033 and reported Fast Track designation, advancing CD122 antagonism for preventing mucosal injury caused by gluten exposure.

Report Coverage

The celiac disease market report covers disease epidemiology, treatment patterns, clinical applications, regional performance, competitive positioning, investment opportunities, emerging technologies, and product development. Segmentation includes 2 treatment categories, First Line of Treatment and Second Line of Treatment, together with Hospital and Clinic applications. Regional analysis covers North America, Europe, Asia Pacific, Middle East & Africa, and Rest of the World.

The report evaluates gluten avoidance, nutritional management, diagnostic pathways, investigational pharmaceuticals, gluten degrading enzymes, TG2 inhibition, IL-15 targeting, CD122 antagonism, and immune tolerance technologies while examining opportunities created by diagnosis expansion, persistent symptoms, accidental gluten exposure, and unmet therapeutic needs.